Cargando…
Xerosis and pruritus as major EGFRI-associated adverse events
PURPOSE: The objective of this sub-analysis of the BeCet study (NCT01136005) was to examine health-related quality of life (HRQoL) of patients experiencing dermatological adverse events (AEs) during the first 6 weeks of epidermal growth factor receptor inhibitor (EGFRI) treatment. METHODS: Patients...
Autores principales: | Clabbers, Julia M. K., Boers–Doets, Christine B., Gelderblom, Hans, Stijnen, Theo, Lacouture, Mario E., van der Hoeven, Koos J. M., Kaptein, Adrian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689742/ https://www.ncbi.nlm.nih.gov/pubmed/26111953 http://dx.doi.org/10.1007/s00520-015-2781-y |
Ejemplares similares
-
Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial
por: Vincenzi, Bruno, et al.
Publicado: (2020) -
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013
por: Wong, Siu-Fun, et al.
Publicado: (2020) -
An Emollient Containing Aquaphilus dolomiae Extract is Effective in the Management of Xerosis and Pruritus: An International, Real-World Study
por: Deleuran, Mette, et al.
Publicado: (2020) -
Epithelial Xerosis in Natives of India
por: Herbert, H.
Publicado: (1897) -
Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open‐label, randomized verification study
por: Yoshida, Yukie, et al.
Publicado: (2021)